ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0455

Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients
Abstract Number: 0178

Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?
Abstract Number: 1423

Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Abstract Number: 1646

Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging
Abstract Number: 0273

Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Abstract Number: 1616

Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Abstract Number: 0107

Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries
Abstract Number: 1536

Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Abstract Number: 0658

ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Abstract Number: 0362

Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Abstract Number: 1895

Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1592

ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
Abstract Number: 0301

Activation of Akt Signaling Pathway in the Minor Salivary Glands of Patients with Primary Sjögren’s Syndrome Does Not Relate with Clinical Phenotype
Abstract Number: 0667

Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Abstract Number: 1253

Acupuncture in Rheumatoid Arthritis Activity

« Previous Page
1
…
4
5
6
7
8
…
132
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].